Optimizing Sustainability in Pharmaceutical Companies with AHP: A Framework for Reducing Carbon Footprints
DOI:
https://doi.org/10.66635/na230f09Keywords:
Sustainability in Pharmaceuticals, Green Building Practices, Fuzzy AHP, Analytic Hierarchy ProcessAbstract
Purpose: The aim of the study is to analyse the key factors that optimize sustainability in pharmaceutical companies. The study seeks to develop a systematic framework that enhances environmental, social, and economic performance within the pharmaceutical sector.
Design/Methodology/Approach: The technique used in this study is a Multi-Criteria Decision-Making method (Fuzzy Analytic Hierarchy Process) to evaluate and prioritize sustainability practices adopted by pharmaceutical companies.
Findings: The study identified Regulatory Compliance and Standards, Transparency and Reporting, and Sustainable Clinical Trials as the most critical factors for optimizing sustainability in pharmaceutical companies. Mid-level contributors included waste minimization, sustainable packaging, and green building practices, while supply chain optimization and product lifecycle management were ranked lower in importance.
Implications: The results suggest that managers should focus on strengthening compliance, transparent reporting, and clinical trial sustainability to achieve meaningful progress. Policymakers may consider reinforcing regulatory frameworks, while socially, greater emphasis on eco-friendly practices and accountability can foster public trust and support long-term sustainability goals.
Originality: This study is novel as it applies a structured decision-making framework (Fuzzy Analytic Hierarchy Process) to systematically rank and evaluate sustainability factors in the pharmaceutical industry, an area where empirical prioritization has been limited.
References
1.Ashworth, B., Du Plessis, M. J., Louise, L., & Van Eeden, J. (2024). The Carbon Footprint of Pharmaceutical Logistics: Calculating Distribution Emissions. Sustainability, 17(2), 760. https://doi.org/10.3390/su17020760
2.Bade, C., Olsacher, A., Boehme, P., Truebel, H., Bürger, L., &Fehring, L. (2023). Sustainability in the pharmaceutical industry—An assessment of sustainability maturity and effects of sustainability measure implementation on supply chain security. Corporate Social Responsibility and Environmental Management, 31(1), 224-242. https://doi.org/10.1002/csr.2564
3.Barakat, B., Milhem, M., Naji, G. M., Alzoraiki, M., Muda, H. B., Ateeq, A., &Abro, Z. (2022). Assessing the Impact of Green Training on Sustainable Business Advantage: Exploring the Mediating Role of Green Supply Chain Practices. Sustainability, 15(19), 14144. https://doi.org/10.3390/su151914144
4.CDP. (2024). CDP: Turning transparency to action. CDP. https://www.cdp.net
5.Chomać-Pierzecka, E. (2022). Pharmaceutical Companies in the Light of the Idea of Sustainable Development—An Analysis of Selected Aspects of Sustainable Management. Sustainability, 15(11), 8889. https://doi.org/10.3390/su15118889
6.European Medicines Agency. (2020). EMA regulatory science to 2025: strategic reflection. EMA. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ema-regulatory-science-2025-strategic-reflection_en.pdfEMA Regulatory Science to 2025
7.Griffiths J, Fox L, Williamson PR (2024). Quantifying the carbon footprint of clinical trials: guidance development and case studies BMJ Open 2024;14:e075755. doi: 10.1136/bmjopen-2023-075755
8.Ibrahim, I. D., Hamam, Y., Sadiku, E. R., Ndambuki, J. M., Kupolati, W. K., Jamiru, T., Eze, A. A., &Snyman, J. (2022). Need for Sustainable Packaging: An Overview. Polymers, 14(20), 4430. https://doi.org/10.3390/polym14204430
9.IQVIA. (2021). Environmental Sustainability in Pharma: A view on Pharma’s progress towards positive impact. IQVIA European Thought Leadership report.
10.Jairoun, A. A., Al-Hemyari, S. S., Shahwan, M., Alkhoujah, S., El-Dahiyat, F., Jaber, A. A. S., &Zyoud, S. H. (2025). Towards eco-friendly pharmaceuticals: Regulatory and policy approaches for sustainable medicines use. Exploratory research in clinical and social pharmacy, 17, 100576. https://doi.org/10.1016/j.rcsop.2025.100576
11.Khan, M (2024) Sustainable Practices in Pharmaceutical Manufacturing. The state of Scientific Marketing, News Medical Life Sciences.
12.Moermond, C. T. A., Puhlmann, N., Brown, A. R., Owen, S. F., Ryan, J., Snape, J., Venhuis, B. J., &Kümmerer, K. (2022). GREENER Pharmaceuticals for More Sustainable Healthcare. Environmental science & technology letters, 9(9), 699–705. https://doi.org/10.1021/acs.estlett.2c00446
13.Moermond, C. T., Puhlmann, N., Brown, A. R., Owen, S. F., Ryan, J., Snape, J., ... &Kümmerer, K. (2022). GREENER pharmaceuticals for more sustainable healthcare. Environmental Science & Technology Letters, 9(9), 699-705.
14.Mostafa, B. A. (2025). The path to sustainability in the pharmaceutical industry: Green HRM’s influence on employee behavior through psychological green climate. Future Business Journal, 11(1), 1-20. https://doi.org/10.1186/s43093-025-00559-x
15.Satta, M., Passarini, F., Cespi, D. et al. Advantages and drawbacks of life cycle assessment application to the pharmaceuticals: a short critical literature review. Environ SciPollut Res (2024). https://doi.org/10.1007/s11356-024-33964-w
16.Wang, L. S., Aziz, Z., Wang, E. S., &Chik, Z. (2024). Unused medicine take-back programmes: A systematic review. Journal of Pharmaceutical Policy and Practice, 17(1), 2395535. https://doi.org/10.1080/20523211.2024.2395535
17.World Health Organization. (2024, December 23). WHO calls for transformative action towards a greener future in pharmaceutical manufacturing and distribution. WHO.
